Home > Result Summaries: Compounds > lamivudine > Result Summary for NUCB2003

Result Summary for NUCB2003

Result Summary

Protocol ID:	NUCB2003
Clinical Study ID:	NUCB2003
Official Title:	A Randomized, Multicentre, Single Blind (Patient) Study to Compare the Efficacy and Safety of 25 mg, 100 mg, and 300 mg Lamivudine, Once daily in patients with Chronic Hepatitis B Infection
Phase:	Phase 2
Study Indications or Diseases:	Hepatitis B, Chronic
Generic Name:	lamivudine
Trade/Product Name:	epivir;epivir
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Nevens F. Main J. Honkoop P. Tyrrell DL. Barber J. Sullivan MT. Fevery J. De Man RA. Thomas HC. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. [Clinical Trial. Journal Article. Randomized Controlled Trial] Gastroenterology. 113(4):1258-63, 1997 Oct..